STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-04-19
Here’s whether Immunovant, Inc. Common Stock (IMVT) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +97.4%; 3-month momentum positive (+11.5%); rising volume confirms the move (1.17x 30d avg). Concerns: RSI 76 — overbought, elevated pullback risk. Currently 0.6% off its 52-week high. Score: +5/7.
IMVT is in a confirmed uptrend, trading above both its 50-day ($25.76) and 200-day ($21.68) moving averages. With an RSI of 75.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +97.4% compares to +35.1% for SPY (beat the market by 62.4%).
$10,000 invested 1 year ago→ $19,744 today
vs. S&P 500 (SPY) — same period beat market by 62.4%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($21.68)
✓Above 50-day MA ($25.76)
!RSI(14) neutral zone (30–70) — currently 75.6
✓Positive return (+97.4%)
✓Within 10% of period high (−0.6%)
Period Range $29.30
$13.36$29.48
RSI (14) 75.6
0 · OversoldOverbought · 100
Key Metrics
Price$29.30
Period Return+97.4%
Period High$29.48
Period Low$13.36
Drawdown−0.6%
MA-50$25.76
MA-200$21.68
RSI (14)75.6
Avg Volume (30d)1.5M
vs. SPYbeat by 62.4%
Return Rank#220 of 996
Trend Signals
Price is above the 200-day moving average ($21.68)